专题：Radiopharmaceutical Chemistry and Applications

This cluster of papers focuses on the development, synthesis, and application of radiopharmaceuticals for PET and SPECT imaging, targeted therapy, radioimmunotherapy, and alpha particle therapy in cancer treatment. It covers topics such as coordinating radiometals, chelators, dosimetry, and the use of specific radionuclides for therapeutic purposes.
最新文献
[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study

article Full Text OpenAlex

Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma

article Full Text OpenAlex

FAPI PET in the Diagnosis and Management of Inflammatory Diseases

review Full Text OpenAlex

Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors

review Full Text OpenAlex

A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation

article Full Text OpenAlex

The evolving landscape of antibody-based cancer therapies: From monospecific to multi-specific and beyond

review Full Text OpenAlex

LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

article Full Text OpenAlex

Folic Acid, Folate Conjugates and Folate Receptors: Novel Applications in Imaging of Cancer and Inflammation-Related Conditions

review Full Text OpenAlex

177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

article Full Text OpenAlex

Chemical Tools to Characterize the Coordination Chemistry of Radionuclides for Radiopharmaceutical Applications

review Full Text OpenAlex

近5年高被引文献
Radiotheranostics in oncology: current challenges and emerging opportunities

review Full Text OpenAlex 424 FWCI12.7999

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

article Full Text OpenAlex 423 FWCI70.2535

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

review Full Text OpenAlex 370 FWCI12.0598

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

article Full Text OpenAlex 357 FWCI103.6911

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

review Full Text OpenAlex 340 FWCI11.3589

[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

review Full Text OpenAlex 322 FWCI10.0026

Advances in PET imaging of cancer

review Full Text OpenAlex 319 FWCI13.5421

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

review Full Text OpenAlex 317 FWCI15.1368

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

article Full Text OpenAlex 310 FWCI51.486

Radiochemistry for positron emission tomography

review Full Text OpenAlex 299 FWCI12.6534